Qingyuan Kaiwu Secures Tens of Millions in Angel Funding, Launches Flagship Product MSSamPro7680 Mass Spectrometry Sample Prep Workstation

VCBeat has learned at the earliest opportunity,Beijing Qingyuan Kaiwu Technology Co., Ltd.(hereinafter referred to as"Qingyuan Kaiwu") upon the establishment of the companySecured two rounds of angel financing within three months, and complete the full closing. The lead investors are respectively under the Beijing Tsinghua Industrial R&D InstituteShuimu Linghang FundandChang Development Zhiheng Direct Investment Fund. The funds obtained will be used for the establishment of R&D teams, the construction of technology platforms, and the research, development, and industrialization of a series of sample pre-processing workstations for sequencing and mass spectrometry, as well as high-end life science equipment.

Qingyuan Kaiwu was established in October 2021, with its R&D base located in the Life Science Park in Changping District. Targeting the unmet demands for highly customized, integrated, automated, and intelligent solutions in the life sciences, biopharmaceutical, and clinical diagnostics markets, the company leverages its founding team’s nearly two decades of experience in innovative product development and commercialization within the IVD sector to provide comprehensive biosample pre-processing solutions for industrial users and hospitals. The company currently focuses onMulti-Dimensional Liquid Control Systemas the core, buildFlexible Modular Technology System, to implement a two-pronged product portfolio strategy:Automated and Intelligent Laboratory EquipmentandHigh-End Life Science Equipment,Focus onSequencing, Mass Spectrometry, Synthetic Biology, and Drug Developmentand other industrial application scenarios.

Company Founder Wang DongGraduated from the Department of Precision Instruments at Tsinghua University, he has been honored with titles such as Capital Sci-Tech Innovation Leading Talent, the First Outstanding Engineer Youth Award of the China International Science Exchange Foundation, Beijing Excellent Young Talent, and Beijing New Star of Science and Technology. He serves as a member of the expert group for the National Key R&D Program on “Proactive Health and Technological Responses to Aging,” Secretary-General of the Medical Instrument Branch of the Chinese Society for Scientific and Technical Instruments, and co-supervisor for master’s students at Tsinghua University and Northwestern Polytechnical University. He works at BioCapital Group, a leading enterprise in gene diagnostics.The Past 20 Years, founded two research institutes successively, and led the completion of projects in gene diagnosis, immune diagnosis, cell testing, and intelligent diagnosis.80+ ItemsProduct development; led multiple ODM projects for international industry giants, and spearheaded several national key R&D programs and projects, receivingOver 20 itemsNMPA, CE, UL, and WEEE certification certificates. Led the team to achieve technological breakthroughs in picoliter- and nanoliter-scale liquid dispensing technology, complete equipment sets for high-throughput microarray chips, and clinical-grade flow cytometers, and spearheaded the formulation of national standards.4 Items, apply for a patentOver 100 items, with profound insights and extensive networks in the life sciences and biopharmaceutical industries.

Leveraging the extensive experience of its founding team, the company has developed a series of products within less than a year of its establishment, including library preparation workstations for high-throughput sequencing, mass spectrometry sample pretreatment workstations for large-scale screening needs, and fully automated nucleic acid detection workstations. These offerings provide automated and intelligent sample pretreatment solutions for life science research and medical testing services. Through a modular, block-style product design philosophy, the related products demonstrate leading advantages in cost control, quality management, operational stability, and spatial integration.

In addition, leveraging Beijing’s abundant scientific research resources and maintaining close collaboration with the life sciences industry cluster, the company has proactively positioned itself in next-generation technologies within the life sciences sector, leading Chinese enterprises in achieving technological breakthroughs in this field. To date, the company has filed more than ten patent applications, and its related products have secured bulk purchase orders from multiple leading industrial clients.

August 1,The First MSSamPro7680 Workstation for Mass Spectrometry Sample PreprocessingTo Be Officially ReleasedThis is a high-throughput, professional-grade automated sample preparation system featuring flexible configuration and four independent functional modules. It enables automated reagent preparation, sample loading, incubation, and liquid handling, allowing for unattended operation. During the process, it can automatically apply pierceable plate seals to 96-well plates to prevent contamination and evaporation. The workstation offers specialized liquid handling capabilities, providing optimized parameters for various liquid types and pipetting volumes. Equipped with two pipettes and one plate gripper, it significantly enhances throughput for microplate replication, dilution, and full-plate processing.

Regarding this financing,Mr. Wu Yong, Managing Partner of Shuimu Venturesstated: “Wang Dong, founder of Qingyuan Kaiwu, has been deeply engaged in the life sciences instrumentation and molecular diagnostics markets for nearly 20 years. The core members of its founding team possess comprehensive backgrounds in the R&D of automation for detection equipment—such as sequencing, mass spectrometry, and flow cytometry—as well as in market operations. They have a profound understanding of the needs of the life sciences and biopharmaceutical industries, along with experience in innovative product development and commercialization. Facing the laboratory automation and high-end life sciences equipment market, which is valued at nearly one trillion yuan, we believe that the Qingyuan Kaiwu team can seize this opportunity to rapidly establish the company as a robust industry leader capable of driving technological advancement among Chinese enterprises.””

Ms. Wang Ying, General Manager of Chang Developmentstated: “Against the backdrop of domestic substitution, Qingyuan Kaiwu has keenly identified the rigid demands and urgent market pain points in the life sciences sector. With a clear and well-defined strategic direction and rapid, effective execution, we will support the company’s development through multiple channels, including ecosystem enterprise matchmaking, industrialization implementation, and policy services.”

Beijing Shuimu Guoding Investment Management Co., Ltd. (hereinafter referred to as “Shuimu Venture Capital”) is a specialized investment institution for the industrialization of scientific and technological achievements, established under the Beijing Tsinghua Industrial Development Institute (hereinafter referred to as the “Industrial Development Institute”). Leveraging the Institute’s nearly 20 years of experience in the transformation and industrialization of scientific and technological achievements, Shuimu Venture Capital promotes the commercialization of major scientific and technological innovations from Tsinghua University through market-oriented approaches and professional management. To date, Shuimu Venture Capital has invested in more than 50 projects, including Tinavi Medical Technologies (688277), the first company listed on the STAR Market in the medical robotics sector; SinoHytec (688339), a leader in China’s hydrogen energy industry; Huazhuo Jingke, a manufacturer of ultra-precision equipment for integrated circuit manufacturing; PINS Medical, a unicorn company in the field of neuromodulation in China; as well as a number of other outstanding enterprises such as Daqing Biology, Jetson Voice, Longsee Instruments, Shenli Technology, Syno Union, and Qingpu Technology.

Over the years, Changfa Development has deeply cultivated Changping District’s leading industries, including healthcare and the broader TMT sector, leveraging market-oriented mechanisms to guide and facilitate the aggregation of diverse financial resources. In 2020, as its fund-of-funds system became increasingly refined, Changfa Development established the Zhiheng Direct Investment Fund, focusing on sectors such as pharmaceuticals and healthcare, information technology, advanced manufacturing, and energy technology. The fund primarily targets early- to mid-stage projects, with selective investments in mature-stage enterprises. By providing core value-chain services across all stages—from product R&D, small-scale and pilot trials, to mass production and after-sales support—Changfa Development offers in-depth industrial support to enterprises. To date, it has completed investments in 16 companies, including Huahui Anjian, Danxu Bio, and Huaxia Yingtai.

As the operator of Changping District’s science and technology industry fund, Chang Development leverages the district’s unique resource advantages through market-oriented and professional operations to establish a complete closed-loop system encompassing fundraising, investment, development, management, and exit. This has resulted in a comprehensive business architecture that integrates a fund-of-funds investment platform, a direct-investment fund platform, direct project investments, post-investment management, and post-investment service support. Currently, in addition to managing three fund-of-funds and the Zhiheng Direct Investment Fund, it has partnered with more than 40 market-oriented equity investment funds, collectively investing in nearly 900 companies with a total valuation approaching RMB 1.5 trillion. Among these, over 40 pharmaceutical and healthcare enterprises in Changping District have received direct or indirect investments totaling more than RMB 1.8 billion, including successfully listed companies such as Aierbo Medical, Genetron Health, Nuocheng Jianhua, and BeiGene.